196 related articles for article (PubMed ID: 33930658)
1. Recurrent ovarian cancer in the era of poly-ADP ribose polymerase inhibitors: time to re-assess established clinical practices.
Bartoletti M; Cecere SC; Musacchio L; Sorio R; Puglisi F; Pignata S
ESMO Open; 2021 Jun; 6(3):100135. PubMed ID: 33930658
[No Abstract] [Full Text] [Related]
2. An update on current and emerging therapies for epithelial ovarian cancer: Focus on poly(adenosine diphosphate-ribose) polymerase inhibition and antiangiogenesis.
Chung C; Lee R
J Oncol Pharm Pract; 2017 Sep; 23(6):454-469. PubMed ID: 27357817
[TBL] [Abstract][Full Text] [Related]
3. Poly-ADP-ribose polymerase (PARP) inhibitors and ovarian function.
Li J; Li Q; Zhang L; Zhang S; Dai Y
Biomed Pharmacother; 2023 Jan; 157():114028. PubMed ID: 36410122
[TBL] [Abstract][Full Text] [Related]
4. U.S. Food and Drug Administration-Approved Poly (ADP-Ribose) Polymerase Inhibitor Maintenance Therapy for Recurrent Ovarian Cancer: A Cost-Effectiveness Analysis.
Dottino JA; Moss HA; Lu KH; Secord AA; Havrilesky LJ
Obstet Gynecol; 2019 Apr; 133(4):795-802. PubMed ID: 30870286
[TBL] [Abstract][Full Text] [Related]
5. Niraparib for the Treatment of Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.
Kerliu L; Myruski S; Bhatti A; Soni P; Petrosius P; Pervanas HC; Horton ER
Ann Pharmacother; 2020 Oct; 54(10):1010-1015. PubMed ID: 32172572
[TBL] [Abstract][Full Text] [Related]
6. Poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors as maintenance therapy in women with newly diagnosed ovarian cancer: a systematic review and meta-analysis.
Cheng H; Yang J; Liu H; Xiang Y
Arch Gynecol Obstet; 2021 Aug; 304(2):285-296. PubMed ID: 34021367
[TBL] [Abstract][Full Text] [Related]
7. PARP (Poly(ADP-Ribose) Polymerase) Inhibitors in Platinum-Sensitive Recurrent Ovarian Cancer: A Meta-Analysis of Randomized Controlled Trials.
Al Hadidi S; Aburahma A; Badami S; Upadhaya S
Oncol Res Treat; 2018; 41(4):226-235. PubMed ID: 29562224
[No Abstract] [Full Text] [Related]
8. Comparison of poly (ADP-ribose) polymerase inhibitors (PARPis) as maintenance therapy for newly-diagnosed and platinum-sensitive recurrent ovarian cancer with
Zhou S; Jiang Y; Luo C; Yuan L
Expert Rev Anticancer Ther; 2024; 24(1-2):59-69. PubMed ID: 38174379
[TBL] [Abstract][Full Text] [Related]
9. Poly(ADP-ribose) polymerase (PARP) inhibitors and ovarian cancer.
Liu CH; Chang Y; Wang PH
Taiwan J Obstet Gynecol; 2017 Oct; 56(5):713-714. PubMed ID: 29037569
[No Abstract] [Full Text] [Related]
10. Cost-effectiveness of poly-(ADP-ribose) polymerase (PARP)-inhibitors for the maintenance treatment after responding to first- and second-line chemotherapy in advanced ovarian cancer.
Giuliani J; Mantoan B; Ferrario L; Candela MV; Aprile G
J Oncol Pharm Pract; 2023 Mar; 29(2):457-464. PubMed ID: 36344039
[TBL] [Abstract][Full Text] [Related]
11. Development of a 3D functional assay and identification of biomarkers, predictive for response of high-grade serous ovarian cancer (HGSOC) patients to poly-ADP ribose polymerase inhibitors (PARPis): targeted therapy.
Sheta R; Bachvarova M; Plante M; Renaud MC; Sebastianelli A; Gregoire J; Navarro JM; Perez RB; Masson JY; Bachvarov D
J Transl Med; 2020 Nov; 18(1):439. PubMed ID: 33213473
[TBL] [Abstract][Full Text] [Related]
12. Clinical Trials of Novel Targeted Therapies in Ovarian Cancer: Moving Beyond Poly ADP Ribose Polymerase (PARP) Inhibitors.
Guo Q; Yang Q; Li J; Liu G; Nikoulin I; Jia S
Curr Pharm Biotechnol; 2018; 19(14):1114-1121. PubMed ID: 30585545
[TBL] [Abstract][Full Text] [Related]
13. [Chinese expert consensus on drug interaction management of poly ADP-ribose polymerase inhibitors].
; ; ; ;
Zhonghua Zhong Liu Za Zhi; 2023 Jul; 45(7):584-593. PubMed ID: 37337129
[TBL] [Abstract][Full Text] [Related]
14. The systemic treatment of recurrent ovarian cancer revisited.
Baert T; Ferrero A; Sehouli J; O'Donnell DM; González-Martín A; Joly F; van der Velden J; Blecharz P; Tan DSP; Querleu D; Colombo N; du Bois A; Ledermann JA
Ann Oncol; 2021 Jun; 32(6):710-725. PubMed ID: 33675937
[TBL] [Abstract][Full Text] [Related]
15. Overview of fuzuloparib in the treatment of ovarian cancer: background and future perspective.
Li N; Liu Q; Tian Y; Wu L
J Gynecol Oncol; 2022 Nov; 33(6):e86. PubMed ID: 36335989
[TBL] [Abstract][Full Text] [Related]
16. Patient cost sharing during poly(adenosine diphosphate-ribose) polymerase inhibitor treatment in ovarian cancer.
Harrison RF; Fu S; Sun CC; Zhao H; Lu KH; Giordano SH; Meyer LA
Am J Obstet Gynecol; 2021 Jul; 225(1):68.e1-68.e11. PubMed ID: 33549538
[TBL] [Abstract][Full Text] [Related]
17. Olaparib beyond progression compared with platinum chemotherapy after secondary cytoreductive surgery in patients with recurrent ovarian cancer: phase III randomized, open-label MITO 35b study, a project of the MITO-MANGO groups.
Schettino C; Musacchio L; Bartoletti M; Chiodini P; Arenare L; Baldassarre G; Califano D; Capoluongo E; Costi MP; D'Incalci M; Marchini S; Mezzanzanica D; Normanno N; Scala S; Greggi S; Perrone F; Pignata S
Int J Gynecol Cancer; 2022 Jun; 32(6):799-803. PubMed ID: 35318277
[TBL] [Abstract][Full Text] [Related]
18. Poly (ADP-ribose) polymerase inhibitors in the management of ovarian cancer.
Markman M
Womens Health (Lond); 2018; 14():1745505717750694. PubMed ID: 29313444
[TBL] [Abstract][Full Text] [Related]
19. The roles and limitations of bevacizumab in the treatment of ovarian cancer.
Nakai H; Matsumura N
Int J Clin Oncol; 2022 Jul; 27(7):1120-1126. PubMed ID: 35477830
[TBL] [Abstract][Full Text] [Related]
20. New Maintenance Treatment for Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.
Aschenbrenner DS
Am J Nurs; 2018 Aug; 118(8):25-26. PubMed ID: 30048284
[No Abstract] [Full Text] [Related]
[Next] [New Search]